Strong sales of cancer drugs and biopharmaceuticals helped push up revenues at AstraZeneca by 10 per cent in the first quarter, as the drugmaker said it would deepen its manufacturing presence in the US.
抗癌藥物和生物製藥的強勁銷售使阿斯特捷利康第一季度的收入成長了10%，這家制藥商表示將深化其在美國的生產業務。
您已閱讀6%（256字），剩餘94%（4337字）包含更多重要資訊，訂閱以繼續探索完整內容，並享受更多專屬服務。